Last reviewed · How we verify
Insulin/Dapaglifozin
Insulin provides glucose control via glucose uptake and metabolism, while dapagliflozin lowers blood glucose by inhibiting renal glucose reabsorption through SGLT2 blockade.
Insulin provides glucose control via glucose uptake and metabolism, while dapagliflozin lowers blood glucose by inhibiting renal glucose reabsorption through SGLT2 blockade. Used for Type 2 diabetes mellitus in patients requiring insulin therapy.
At a glance
| Generic name | Insulin/Dapaglifozin |
|---|---|
| Sponsor | University of Campania Luigi Vanvitelli |
| Drug class | Insulin + SGLT2 inhibitor combination |
| Target | Insulin receptor; SGLT2 (sodium-glucose cotransporter 2) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
This is a combination therapy where insulin acts as an exogenous hormone to facilitate cellular glucose uptake and utilization, while dapagliflozin, an SGLT2 inhibitor, works independently by blocking sodium-glucose cotransporter 2 in the proximal tubule, causing urinary glucose excretion. The combination targets hyperglycemia through complementary mechanisms: insulin addresses intracellular glucose metabolism and dapagliflozin enhances renal glucose clearance.
Approved indications
- Type 2 diabetes mellitus in patients requiring insulin therapy
Common side effects
- Hypoglycemia
- Genital mycotic infections
- Urinary tract infections
- Diabetic ketoacidosis
- Volume depletion
Key clinical trials
- Study to Explore the Effect of Dapagliflozin and Stress in Adolescent and Adult Subjects With Type 1 Diabetes (T1D) (PHASE1)
- Durability of Combination of Insulin and GLP-1 Receptor Agonist or SGLT-2 Inhibitors Versus Basal Bolus Insulin Regimen in Type 2 Diabetes (BEYOND) (PHASE4)
- Phase 1 Study to Explore the Safety and Pharmacokinetics of DAPAglifozin in Adolescents and Adults With Type 1 Diabetes (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Insulin/Dapaglifozin CI brief — competitive landscape report
- Insulin/Dapaglifozin updates RSS · CI watch RSS
- University of Campania Luigi Vanvitelli portfolio CI